Gilead Sciences (GILD) News Today → Secret energy grid to power millions of homes (From Porter & Company) (Ad) Free GILD Stock Alerts $64.70 +0.85 (+1.33%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 8 at 10:36 AM | marketbeat.comEpoch Investment Partners Inc. Acquires 247,652 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Epoch Investment Partners Inc. boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 49.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 748,071 shares of the biopharmaceutical coJune 8 at 6:50 AM | fool.com3 Stocks With Mouthwatering Dividends You Can Buy Right NowJune 7 at 9:55 PM | marketbeat.comSchroder Investment Management Group Buys 132,679 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Schroder Investment Management Group grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,646,589 shares of the biopharmaceutical companyJune 6 at 10:12 PM | marketbeat.comCibc World Markets Corp Cuts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Cibc World Markets Corp cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 453,247 shares of the biopharmaceutical company's stock after sellingJune 6 at 12:19 PM | marketbeat.comTop Biotech Stocks: Exploring Innovation Opportunities (GILD)One fascinating sector to invest in is the biotech sector which includes companies involved in the research and development of therapeutics and vaccinesJune 6 at 7:46 AM | americanbankingnews.comQ3 2025 Earnings Forecast for Gilead Sciences, Inc. (NASDAQ:GILD) Issued By Zacks ResearchJune 6 at 7:45 AM | marketbeat.comGilead Sciences, Inc. to Post Q3 2025 Earnings of $2.06 Per Share, Zacks Research Forecasts (NASDAQ:GILD)Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Equities research analysts at Zacks Research boosted their Q3 2025 earnings per share estimates for shares of Gilead Sciences in a research note issued on Monday, June 3rd. Zacks Research analyst E. Bagri now anticipates that the biopharmaceuticJune 6 at 4:30 AM | businesswire.comGilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNAJune 6 at 1:30 AM | americanbankingnews.comGilead Sciences, Inc. (NASDAQ:GILD) to Post Q2 2024 Earnings of $1.51 Per Share, Zacks Research ForecastsJune 5 at 5:32 PM | marketbeat.comTower Research Capital LLC TRC Has $16.29 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Tower Research Capital LLC TRC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 208.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 201,060 shares of the biopharmaceutical company's stock afterJune 5 at 2:05 PM | seekingalpha.comGilead Sciences, Inc. (GILD) Jefferies 2024 Global Healthcare ConferenceJune 5 at 9:45 AM | fool.comShould You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100?June 5 at 7:00 AM | investorplace.comThe Dividend Dynamos: 7 Stocks That Will Energize Your Income StreamJune 5 at 6:40 AM | investorplace.com7 Dividend Stocks to Invest In for a Lifetime of IncomeJune 5 at 6:08 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Forecasted to Post Q2 2024 Earnings of $1.51 Per ShareGilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Equities research analysts at Zacks Research lifted their Q2 2024 earnings per share estimates for shares of Gilead Sciences in a research report issued on Monday, June 3rd. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutiJune 5 at 2:00 AM | businesswire.comGilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary CholangitisJune 4, 2024 | marketbeat.comRhenman & Partners Asset Management AB Purchases 25,000 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Rhenman & Partners Asset Management AB increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 10.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 259,000 shJune 4, 2024 | investorplace.com3 Dividend Stocks That Even Ken Griffin Is BuyingJune 3, 2024 | marketbeat.comRafferty Asset Management LLC Raises Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Rafferty Asset Management LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 375,148 shares of the biopharmaceutical cJune 3, 2024 | businesswire.comEncouraging New Data Presented on Kite's Yescarta® for Relapsed/Refractory Central Nervous System LymphomaJune 2, 2024 | marketbeat.comEagle Asset Management Inc. Purchases 60,697 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Eagle Asset Management Inc. increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 23.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 317,539 shares of the biopharmaceutical company's sJune 2, 2024 | businesswire.comZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated ComputingJune 2, 2024 | businesswire.comGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerJune 2, 2024 | businesswire.comGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerJune 2, 2024 | americanbankingnews.comGilead Sciences (NASDAQ:GILD) Shares Gap Down to $64.08June 1, 2024 | marketbeat.comBank of Nova Scotia Buys 130,552 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Bank of Nova Scotia boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 43.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 427,751 shares of the biopharmaceutical company's stock after buying an additional 13June 1, 2024 | businesswire.comGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersJune 1, 2024 | businesswire.comGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersJune 1, 2024 | americanbankingnews.comGilead Sciences, Inc. (NASDAQ:GILD) Receives $83.69 Consensus Target Price from BrokeragesMay 31, 2024 | marketbeat.comParnassus Investments LLC Has $968.24 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Parnassus Investments LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 11,952,057 shares of the biopharmaceutical company's stock after purchasing an additional 36,686May 31, 2024 | benzinga.comGilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder CancerMay 31, 2024 | reuters.comGilead's Trodelvy extends lung cancer survival by just 1.3 months in trialMay 31, 2024 | businesswire.comEVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024May 30, 2024 | reuters.comGilead's Trodelvy fails to meet main goal in late-stage studyMay 30, 2024 | businesswire.comGilead Provides Update on Phase 3 TROPiCS-04 StudyMay 30, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by TD Asset Management IncTD Asset Management Inc lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,029,657 shares of the biopharmaceutical cMay 29, 2024 | marketbeat.comTFO Wealth Partners LLC Acquires 16,006 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)TFO Wealth Partners LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 29,640.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,060 shares of the biopharmaceuticaMay 29, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Rating of "Hold" from AnalystsGilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) has been assigned an average rating of "Hold" from the seventeen ratings firms that are presently covering the stock, Marketbeat Ratings reports. Eleven research analysts have rated the stock with a hold recommendation and six have assigned a bMay 28, 2024 | marketbeat.comGilead Sciences (NASDAQ:GILD) Reaches New 52-Week Low at $64.19Gilead Sciences (NASDAQ:GILD) Reaches New 12-Month Low at $64.19May 28, 2024 | seekingalpha.comGilead Sciences: Seriously Undervalued At Peak PessimismMay 28, 2024 | finance.yahoo.comGilead Sciences Partners With White House for Early Cancer Detection Program "Biden Cancer Moonshot"May 28, 2024 | fool.com2 Beaten-Down Dividend Stocks to Buy and Hold For 10 YearsMay 28, 2024 | businesswire.comCartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies Against Novel Targets and Target PairsMay 27, 2024 | marketbeat.comUnited Services Automobile Association Buys 90,194 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)United Services Automobile Association lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 67.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 222,985 shares of the biopharmaMay 27, 2024 | seekingalpha.comUnloved Gilead Due For Reversal On Flight-To-Safety Money FlowsMay 27, 2024 | seekingalpha.comUnloved Gilead Due For Reversal On Flight-To-Safety Money FlowsMay 26, 2024 | marketbeat.comIntech Investment Management LLC Sells 141,024 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Intech Investment Management LLC lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 27.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 373,106 sharesMay 25, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Advisory Services Network LLCAdvisory Services Network LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 75,434 shares of the biopharmaceutical company's stock after sellMay 24, 2024 | marketbeat.comNomura Asset Management Co. Ltd. Purchases 14,557 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Nomura Asset Management Co. Ltd. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 906,670 shares of the biopharmaceutical company's stock after purchaMay 24, 2024 | barrons.comCancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know. Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address A New Generation of Billionaires Is About to Be Created (Ad)On June 30, AI will hit a tipping-point… $15.7 trillion of wealth is at stake. As many as 800 million jobs are caught in AI’s crosshairs… Click here for details. Related Videos GILD Media Mentions By Week GILD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GILD News Sentiment▼0.810.72▲Average Medical News Sentiment GILD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GILD Articles This Week▼3216▲GILD Articles Average Week Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MRNA News Today SGEN News Today TECH News Today QGEN News Today CRSP News Today DNLI News Today AMGN News Today VRTX News Today REGN News Today BIIB News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GILD) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersWe’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from the...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gilead Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
